Related Experiment Video
Updated: Jun 19, 2026
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer
Kazuyoshi Yamamoto1, Yoshiyuki Fujiwara, Toshiro Nishida
1Division of Gastroenterological Surgery, Department of Surgery, Graduate School of Medicine, Osaka University, 2-2, E2, Yamadaoka, Suita, Osaka 565-0871, Japan.
Background:
The aim of this study was to evaluate the feasibility and efficacy of modified triplet chemotherapy with docetaxel, 5-fluorouracil and cisplatin as induction chemotherapy for advanced gastric cancer (AGC).
Patients And Methods:
Treatment-naïve patients with AGC were eligible. The regimen consisted of 350 mg/m(2)/day 5-FU by continuous infusion on days 1 to 5, 10 mg/m(2)/day CDDP intravenously on days 1 to 5, and docetaxel at 60 mg/m(2)/day intravenously on day 1. After 2 cycles (each cycle consisted of 4 weeks), surgical resection was attempted, 2-4 weeks after the completion of the regimen.
Results:
Eighteen patients were enrolled. Adverse events included grade 3 anorexia and nausea in 16.7% and 11.1% and grade 4 leukocytopenia and neutropenia in 5.6% and 27.8%, respectively. The overall response rate was 44.4%. Surgery was conducted in 15 patients. The 1- and 3-year survival rates were 75.6% and 51.1%, respectively.
Conclusion:
The modified triplet combination therapy is effective and well tolerated by patients with AGC.
